Xeris Biopharma Holdings, Inc.
XERS
$7.59
$0.020.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 19.00% | 0.03% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 19.00% | 0.03% | |||
| Cost of Revenue | 36.32% | -7.91% | |||
| Gross Profit | 16.05% | 1.52% | |||
| SG&A Expenses | 0.85% | 29.32% | |||
| Depreciation & Amortization | 0.04% | -0.04% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.09% | 20.81% | |||
| Operating Income | 245.05% | -139.72% | |||
| Income Before Tax | 79.09% | -80.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 79.09% | -80.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 79.09% | -80.32% | |||
| EBIT | 245.05% | -139.72% | |||
| EBITDA | 11,666.15% | -100.60% | |||
| EPS Basic | 80.00% | -76.38% | |||
| Normalized Basic EPS | 79.89% | -1,021.95% | |||
| EPS Diluted | 80.00% | -76.38% | |||
| Normalized Diluted EPS | 79.89% | -1,021.95% | |||
| Average Basic Shares Outstanding | 4.60% | 2.25% | |||
| Average Diluted Shares Outstanding | 4.60% | 2.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||